Antigen-binding molecule containing modified antibody variable region
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsTomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
Life of this patent
Estimating the term…
Abstract
The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.
Claims19
An antigen-binding molecule comprising a first antibody variable region comprising a first antigen-binding site and a second antigen-binding site, wherein:
- (a) the first antigen-binding site recognizes a first antigen that is human CD3;
- (b) the second antigen-binding site recognizes a second antigen that is a human Toll-like receptor 2;
- (c) the first antigen-binding site cannot bind to the first antigen when the second antigen-binding site is bound to the second antigen;
- (d) the second antigen-binding site cannot bind to the second antigen when the first antigen-binding site is bound to the first antigen;
- and
- (e) the first antibody variable region comprises:
- a heavy chain variable domain comprising the heavy chain variable domain amino acid sequence in any one of SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39 and SEQ ID NO:
- 40, and
- a light chain variable domain comprising the light chain variable domain amino acid sequence in SEQ ID NO:
- 23.
Dependencies are inferred from the claim text.